- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: Body psychotherapy.
Displaying page 1 of 1.
EudraCT Number: 2018-001718-13 | Sponsor Protocol Number: MP18 | Start Date*: 2019-10-18 |
Sponsor Name:MAPS Europe B.V. | ||
Full Title: An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis... | ||
Medical condition: post-traumatic stress disorder (PTSD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) CZ (Completed) NO (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2022-003381-21 | Sponsor Protocol Number: RAFAEL | Start Date*: 2023-09-11 |
Sponsor Name:Psyon, s.r.o. | ||
Full Title: Regression of atherosclerosis induced by life changing experience with psilocybin | ||
Medical condition: Ischemic Heart Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003279-41 | Sponsor Protocol Number: PSY-NIL-0013 | Start Date*: 2023-03-31 |
Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy | ||
Full Title: Investigating N-methyl-d-aspartate (NMDA) receptor alterations in major depressive disorder by brain PET | ||
Medical condition: Major Depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000805-26 | Sponsor Protocol Number: PSYKFORSK_MAT-MDD | Start Date*: 2021-11-19 |
Sponsor Name:Østfold Hospital Trust | ||
Full Title: An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder | ||
Medical condition: Major Depressive Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006200-33 | Sponsor Protocol Number: CLA-PSY-201 | Start Date*: 2022-09-22 | |||||||||||
Sponsor Name:Clairvoyant Therapeutics Inc. | |||||||||||||
Full Title: A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with A... | |||||||||||||
Medical condition: Alcohol use disorder (AUD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004586-41 | Sponsor Protocol Number: CHUBX2012/16 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:CHU de Bordeaux | |||||||||||||
Full Title: Cognitive remediation in Attention Deficit Disorder with or without Hyperactivity (ADHD) children : Comparison between three therapeutic strategies : cognitive remediation with a virtual classroom ... | |||||||||||||
Medical condition: Attention Deficit Disorder with or without Hyperactivity | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003469-20 | Sponsor Protocol Number: CL07-ORY-2001 | Start Date*: 2020-11-06 | |||||||||||
Sponsor Name:Oryzon Genomics S.A. | |||||||||||||
Full Title: A double blind, randomized, placebo-controlled, adaptive 14-week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (POR... | |||||||||||||
Medical condition: Borderline Personality Disorder (BPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004880-33 | Sponsor Protocol Number: 18F-FDOPA-BUP-ESC | Start Date*: 2023-01-20 |
Sponsor Name:Medical University of Vienna, University Department of Psychiatry and Psychotherapy | ||
Full Title: Reward-specific changes of cerebral dopamine synthesis in healthy volunteers and depressed patients | ||
Medical condition: Major Depression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001398-19 | Sponsor Protocol Number: Exposition-DCS | Start Date*: 2011-06-27 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: D-cycloserine augmented exposure therapy in patients with agoraphobia | ||
Medical condition: agarophobia with or without panic disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004079-38 | Sponsor Protocol Number: 01112012 | Start Date*: 2013-01-14 |
Sponsor Name:Central Institute of Mental Health, Department of Psychiatry and Psychotherapy | ||
Full Title: Agomelatine treatment of major depressive episodes in the course of schizophrenic psychoses (AGOPSYCH). A single arm, prospective pilot study | ||
Medical condition: Major depressive episode | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-002757-26 | Sponsor Protocol Number: BH-200-03 | Start Date*: 2023-03-28 | |||||||||||
Sponsor Name:HMNC Holding GmbH | |||||||||||||
Full Title: A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) DE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003038-34 | Sponsor Protocol Number: D1002001 | Start Date*: 2015-07-07 | |||||||||||
Sponsor Name:Sumitomo Dainippon Pharma Co., Ltd. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression | |||||||||||||
Medical condition: Bipolar I depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003369-16 | Sponsor Protocol Number: GWAP19030 | Start Date*: 2020-06-02 |
Sponsor Name:GW Research Ltd. | ||
Full Title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate... | ||
Medical condition: Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk o... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2022-003743-10 | Sponsor Protocol Number: BPL-003-201 | Start Date*: 2023-06-22 | |||||||||||
Sponsor Name:Beckley Psytech Ltd. | |||||||||||||
Full Title: A Quadruple Masked, Dose-Finding Study to Evaluate the Efficacy and Safety of Intranasal BPL-003, with Open Label Extension, in Patients with Treatment Resistant Depression | |||||||||||||
Medical condition: Treatment-Resistant Depression (TRD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005134-21 | Sponsor Protocol Number: HP-3070-GL-04 | Start Date*: 2016-07-01 | |||||||||||
Sponsor Name:Noven Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006861-39 | Sponsor Protocol Number: GH001-BD-202 | Start Date*: 2022-06-20 | |||||||||||
Sponsor Name:GH Research Ireland Limited | |||||||||||||
Full Title: A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode (GH001-BD-202) | |||||||||||||
Medical condition: Bipolar II Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
